Introduction: Teriparatide (rhPTH 1-34) is a recombinant human parathyroid hormone derivative consisting of the first 34 amino acids of the hormone. Teriparatide was approved as a drug by the FDA and is sold by Eli Lilly & Co. as Forteo. Teriparatide is indicated for use in patients with osteoporosis. Immunogenicity for this drug, was detected in 2.8% of women receiving Teriparatide during clinical trials of Forteo. The detection of these circulating antibodies may be of clinical relevance for the proper assessment of patients. Intended Use: This Anti-PTH Antibody ELISA is a rapid and easy method for the qualitative determination of Anti-PTH Antibody in human serum and plasma. Principle: The method employs the quantitative sandwich enzyme immunoassay technique. PTH is pre-coated onto microwells. Samples and standards are pipetted into microwells and human Anti-PTH Antibody present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated PTH is pipetted and incubated with samples. After washing microwells in order to remove any nonspecific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Anti-PTH Antibody in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
Additional information
| Sample Type | Serum and Plasma |
|---|---|
| Calibration Range | Quantitative |
| Storage Temperature | The samples may be kept at 2 – 8 Degree Celcius for up to three days. Long-term storage requires – 20 Degree Celcius. |
| Regulatory Status | Research Use Only available |
| Detection Method | Colorimetric |
